A new trading day began on Thursday, with Nektar Therapeutics (NASDAQ: NKTR) stock price up 4.88% from the previous day of trading, before settling in for the closing price of $0.61. NKTR’s price has ranged from $0.43 to $1.93 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -0.50% over the last five years. Meanwhile, its annual earnings per share averaged -13.65%. With a float of $179.37 million, this company’s outstanding shares have now reached $185.78 million.
The firm has a total of 61 workers. Let’s measure their productivity. In terms of profitability, gross margin is 68.82%, operating margin of -92.39%, and the pretax margin is -121.1%.
Nektar Therapeutics (NKTR) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Nektar Therapeutics is 3.62%, while institutional ownership is 69.45%. The most recent insider transaction that took place on Feb 19 ’25, was worth 10,403. In this transaction Chief R&D Officer of this company sold 10,300 shares at a rate of $1.01, taking the stock ownership to the 316,604 shares. Before that another transaction happened on Feb 19 ’25, when Company’s Chief Legal Officer sold 11,040 for $1.01, making the entire transaction worth $11,150. This insider now owns 324,292 shares in total.
Nektar Therapeutics (NKTR) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.18 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -13.65% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -15.48% during the next five years compared to 25.49% growth over the previous five years of trading.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
Here are Nektar Therapeutics’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.20.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.58, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.80 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Analysing the last 5-days average volume posted by the [Nektar Therapeutics, NKTR], we can find that recorded value of 3.51 million was better than the volume posted last year of 2.31 million. As of the previous 9 days, the stock’s Stochastic %D was 78.50%. Additionally, its Average True Range was 0.08.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 25.17%, which indicates a significant decrease from 72.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 131.03% in the past 14 days, which was higher than the 89.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7696, while its 200-day Moving Average is $1.0758. Now, the first resistance to watch is $0.6622. This is followed by the second major resistance level at $0.6880. The third major resistance level sits at $0.7191. If the price goes on to break the first support level at $0.6053, it is likely to go to the next support level at $0.5742. Now, if the price goes above the second support level, the third support stands at $0.5484.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
With a market capitalization of 118.44 million, the company has a total of 186,104K Shares Outstanding. Currently, annual sales are 98,430 K while annual income is -118,960 K. The company’s previous quarter sales were 29,180 K while its latest quarter income was 7,260 K.
